Tuesday, September 16, 2025 9/16/2025

Advancing standards and methodologies to generate real world evidence from real world data through a neonatal pilot project

Award Number: U01FD007220
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2024

Group Awards By:

View Award Description

Advancing standards and methodologies to generate real world evidence from real world data through a neonatal pilot project - Critical Path Institute Proposal for RFA-FD-20-030 ABSTRACT Historically, FDA has utilized real-world evidence (RWE) as a key component of its efforts to assure post-marketing surveillance and evaluation of medical product safety. The 21st Century Cures Act mandates FDA to develop a framework that expands the use of RWD and RWE to support approvals of a new indications for an already approved drug. By leveraging data generated through the normal practice of medicine, signals of safety and efficacy for new indications can be identified in already approved therapies. However, as most existing RWD was generated without the regulatory standards in mind, significant challenges exist to ensure RWD is fit-for-purpose to generate RWE capable of informing regulatory decisions. Efforts to use existing RWD to answer regulatory questions can identify these challenges and corresponding solutions, but this endeavor requires a significant amount of data and regulatory science expertise to fully optimize the use of RWD to extract actionable RWE. The Critical Path Institute (C-Path) has that data expertise and will execute a pilot project to facilitate the use of RWD to generate RWE in neonates, with learnings being broadly applicable to other therapeutic areas. Each year in the U.S., 10% of neonates are born preterm and there is an urgent need to improve survival and outcome. However, there is minimal new drug development and most existing drugs have insufficient evidence to support safety, efficacy, and dosage in this high-risk population. C-path will leverage its Data Collaboration Center processes and infrastructure to develop an RWD Analytics Platform. RWD will be accessed through collaborations with investigators and data scientists. Specific algorithms and mechanisms will be implemented to extract RWD from relevant sources (aggregated databases and EMRs), curate and standardize data, and enable analyses to generate actionable RWE. When data are analyzed remotely, C-Path will validate processing workflows for quality assurance. Data thus extracted will address two key unmet needs in the neonatal population: 1) current lack of actionable reference values for routine laboratory tests (as a function of gestational/postnatal age) and 2) lack of disease progression model for bronchopulmonary dysplasia. A gaps analysis will identify key lessons specific to neonates relating to the access, quality, extraction, curation, standardization, and analysis of RWD, and potential solutions to optimally generate actionable RWE identified, and shared with key stakeholders in the neonatal community. Lessons learned with this high-risk population can then be generalized to other therapeutic areas.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	THE CRITICAL PATH INSTITUTE	1840 E RIVER RD	TUCSON	AZ	85718	PIMA	USA	Food and Drug Administration Research	000	3	7/8/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $1,571,802 )
2022	2022	CRITICAL PATH INSTITUTE, THE	1730 E RIVER RD STE 200	TUCSON	AZ	85718	PIMA	USA	Food and Drug Administration Research	000	3	7/7/2022	NON-COMPETING CONTINUATION	$1,571,802
														Subtotal = $1,571,802

Issue Date FY: 2021 ( Subtotal = $1,748,239 )
2021	2021	CRITICAL PATH INSTITUTE, THE	1730 E RIVER RD STE 200	TUCSON	AZ	85718	PIMA	USA	Food and Drug Administration Research	000	2	7/9/2021	NON-COMPETING CONTINUATION	$1,748,239
														Subtotal = $1,748,239

Issue Date FY: 2020 ( Subtotal = $1,777,287 )
2020	2020	CRITICAL PATH INSTITUTE, THE	1730 E RIVER RD STE 200	TUCSON	AZ	85718	PIMA	USA	Food and Drug Administration Research	000	1	8/31/2020	NEW	$1,777,287
														Subtotal = $1,777,287

Grand Total All Awards = $5,097,328

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advancing standards and methodologies to generate real world evidence from real world data through a neonatal pilot project

Award Number: U01FD007220

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer